The unbalanced translocation, der(1;7)(q10;p10), is one of the characteristic cytogenetic abnormalities found in myelodysplastic syndromes (MDS) and other myeloid neoplasms. Although described frequently with very poor clinical outcome and possible relationship with monosomy 7 or 7q-(À7/7q-), this recurrent cytogenetic abnormality has not been explored fully. Here we analyzed retrospectively 77 cases with der(1;7)(q10;p10) in terms of their clinical and cytogenetic features, comparing with other 46 adult À7/7q-cases without der(1;7)(q10;p10). In contrast with other À7/7q-cases, where the abnormality tends to be found in one or more partial karyotypes, der(1;7)(q10;p10) represents the abnormality common to all the abnormal clones and usually appears as a sole chromosomal abnormality during the entire clinical courses, or if not, is accompanied only by a limited number and variety of additional abnormalities, mostly trisomy 8 and/or loss of 20q. der(1;7)(q10;p10)-positive MDS cases showed lower blast counts (Po0.0001) and higher hemoglobin concentrations (Po0.0075) at diagnosis and slower progression to acute myeloid leukemia (P ¼ 0.0043) than other À7/7q-cases. der(1;7)(q10;p10) cases showed significantly better clinical outcome than other À7/7q cases (Po0.0001). In conclusion, der(1;7)(q10;p10) defines a discrete entity among myeloid neoplasms, showing unique clinical and cytogenetic characteristics. Leukemia (2007) 21, 992-997.
Introduction
The unbalanced translocation, der(1;7)(q10;p10), is a nonrandom chromosomal abnormality found in myelodysplastic syndromes (MDS) as well as acute myeloid leukemia (AML), and less frequently in myeloproliferative disorders (MPD). 1 It is presented typically with an International System for Chromosome Nomenclature (2005) description, 2 46,XY(or XX), þ 1,der(1;7)(q10;p10) and characterized by the presence of one of the two possible derivative chromosomes with two copies of apparently normal chromosome 1 and a single copy of the intact chromosome 7, leading to allelic imbalance of trisomy 1q and monosomy 7q. It was found consistently in 1.5-6% in MDS, 0.2-2.1% in AML and rarely in MPD depending on the literature. [3] [4] [5] [6] [7] [8] [9] Detailed molecular studies using quantitative fluorescent in situ hybridization analysis disclosed that the translocation is likely to occur through a mitotic recombination within the large clusters of homologous centromere alphoid sequences, D1Z7 on chromosome 1 and D7Z1 on chromosome 7. The breakpoints are widely distributed within these alphoids clusters but typically spare the short arm third of both alphoids, suggesting that it may not be a dicentric chromosome but that der(1;7)(q10,q10) is a more appropriate karyotypic description for this translocation. 10 On the other hand, however, the clinical aspect of this translocation is less clearly defined compared with its genomic structure. While the common clinical features thus far reported include a previous history of chemo-and/or radiotherapies in more than half cases, [11] [12] [13] presence of eosinophilia, 13 trilineage dysplasia, high rates of progression to AML in MDS cases and poor prognosis with less than 1 year of median survival, 3, 14, 15 these features have not been fully investigated because of the rarity of this translocation compared with other well-characterized cytogenetic groups found in AML/MDS. Also it is unclear that its pathogenetic link to monosomy 7 or partial deletion of 7q (À7/7q-) other than der(1;7)(q10;p10), although some authors speculated that der(1;7)(q10;p10) represents a mere variant of the former.
In this paper, to clarify these points, we analyzed retrospectively 77 cases with der(1;7)(q10;p10) for their clinical and genetic/cytogenetic characteristics in comparison with other 46 cases with À7/7q-. A literary review of 125 der(1;7)(q10;p10) cases was also provided.
Materials and methods

Patients
The patients included in this study are those who were diagnosed and treated as having MDS, AML and MPD at one of the collaborating hospitals during 1 January 1990 through 30 September 2005, for whom at least one cytogenetic report showed either der(1;7)(q10;p10), monosomy 7, or other unbalanced abnormalities showing loss of genetic materials of the long arm of chromosome 7. À7/7q-was required to be confirmed in at least three independent karyotypes, whereas other abnormalities were found in at least two karyotypes. 2 Complex karyotypes were defined by the presence of more than two independent karyotypes with at least three unrelated aberrations according to the previous studies. 16, 17 Clinical records were reviewed retrospectively at each hospital according to the above criteria and after fully anonymized, the cases who met the criteria were reported according to an indicated form with regard to patients' age, sex, diagnosis (FrenchAmerican-British (FAB)), date of diagnosis, cytogenetics (G-banding), histories of chemo-radiotherapies, cellularity and blast counts of bone marrow, complete peripheral blood counts at diagnosis, presence or absence of leukemic transformation, and date and cause of death. The list of the collaborating hospitals is the Hematology unit of Akita University Hospital and Dokkyo University Hospital, Honma Hospital, Jichi Medical School Hospital, National Kyushu Cancer Center, Nishio Municipal Hospital, Saitama Medical School Hospital, Showa University Fujigaoka Hospital, Tokyo Medical School Hospital, the Hospital of Tokyo Women's Medical University and the University of Tokyo Hospital. The diagnosis and sub-classification of MDS and AML at each collaborating hospital were made according to the FAB criteria. 18 Mutation study was performed for 20 cases each with der(1;7)(q10;p10) and À7/7q-, for which genomic DNA from bone marrow was available. Another 20 MDS cases showing normal karyotypes were also subjected to the mutation analysis, according to the approval from the ethical committee, University of Tokyo (Approval No. 948-1).
Statistical analysis
The statistical difference in each clinical feature between der(1;7)(q10;p10) and other À7/7q cases was tested by 2 Â 2 contingency tables using the Fischer's exact test or the Student's t-test. Overall survival was estimated using the Kaplan-Meier method and the statistic significance was calculated using logrank tests. After possible association with overall survival was individually tested for a number of variables, including age, bone marrow blasts, peripheral blood counts, chromosomal abnormalities and history of anticancer therapies, proportional hazard modeling was used for identifying the independent risk factors that influence overall survival, where those factors that showed potential significance in the univariate tests with Po0.10 were subjected to the multivariate analysis using backward stepwise selection of covariates. All P-values were two-sided and P-values of 0.05 or o0.05 were considered statistically significant.
Mutation analysis
Mutation status of the runx1/AML1 and N-ras genes was tested on aforementioned 60 cases. Exons 3, 4, 5, 6, 7b and 8 of the runx1 gene and exons 1 and 2 of the N-ras gene were amplified from genomic DNA by polymerase chain reaction (PCR) as described previously. 19, 20 Sequencing was performed using an ABI Prism 3100 Genetic Analyzer with the same primers as used in PCR amplification.
Literary review of der(1;7)(q10;p10) cases Reported cases of der(1;7)(q10;p10) were retrieved from the Mitelman Database of Chromosome Aberrations in Cancer 2006 21 according to the following karyotypic descriptions: der(1;7)(q10;p10); der(1)t(1;7)(p11;p11); þ t(1;7)(p11;p11),À7; der(1;7)(p10;q10); and dic(1;7)(p11;q11).
Results
Patients' characteristics
In total, 123 cases, including 22 AML, 98 MDS and 3 MPD, were analyzed. The demographic features of these 123 cases are summarized in Table 1 . Seventy-seven cases were der(1;7)(q10;p10), which contain 20 cases reported previously. 22, 23 The other 46 cases had -7/7q-other than der(1;7)(q10;p10). Strong male predominance was evident in both groups, especially in der(1;7)(q10;p10). The cases having der(1;7)(q10;p10) accounted for 2.3% (10 cases) of 427 cases who were diagnosed as having AML or MDS at the University of Tokyo Hospital. À7/7q-was found in 38 cases among the 427 cases, of which 22 and 16 cases were diagnosed as having MDS and AML, respectively. Both showed a high median age of the disease onset but it was higher in der(1;7)(q10;p10) than for -7/7q-(P ¼ 0.0027). In our series, 32.9% of der(1;7)(q10;p10) and 25.0% of -7/7q-cases had one or more prior histories of chemotherapies and/or radiotherapies for some malignancies. In both groups, more cases are diagnosed as MDS than as AML. Increased eosinophil counts in der(1;7)(q10;p10) have been underscored in some literatures, 13, 24, 25 but in our series it was not so conspicuous and only six der(1;7)(q10;p10) and one -7/7q-cases had prominent eosinophilia (4450/ml).
Cytogenetic features
Karyotypic analysis revealed a number of cytogenetic features which contrast der(1;7)(q10;p10) to other 7q-abnormalities (Supplementary Table 1 and 2). der(1;7)(q10;p10) was always present at the time of clinical diagnosis and even when multiple subclones exist, it involves all the abnormal karyotypes. In 45 (58.4%) cases, it appeared as a sole chromosomal abnormality during the observation periods. The remaining 32 cases had additional chromosomal abnormalities, but they were limited in number and mostly consisted of trisomy 8 (18 cases) and/or loss of 20q (10 cases). In contrast, À7/7q-appeared as the solitary abnormality was less common (28.3%) and it was more typically accompanied by other frequently complex abnormalities, where 24 of the 46 À7/7q-cases showed more than four additional unrelated chromosomal abnormalities. Indeed, the mean number of additional abnormalities was significantly higher in the À7/7q cases than in der(1;7)(q10;p10) cases (Po0.0001) ( Table 1) . Moreover, in some cases, it appeared only in partial karyotypes (À7/7q-cases 5, 6, 22, 23, 28, 31 and 35) and evolved during the course of the diseases. 5q-was the most common abnormality that was found in association with À7/7q-(23/46), whereas trisomy 8 and 20q-were very rare in this group.
der(1;7)(q10;p10) in MDS Since the majority of cases in this study were diagnosed as MDS (FAB classification 18 ), it is of interest to focus the analysis on those cases having MDS (Table 2 ). In fact, clinical features were considerably different between both cytogenetic groups in MDS. According to the FAB classification, der(1;7)(q10;p10) cases were more likely to be classified into RA (P ¼ 0.0002), whereas RAEB/RAEB-t were the leading diagnosis in the -7/7q-group (P ¼ 0.0003). Similarly, der(1;7)(q10;p10) cases were more frequently classified into favorable risk groups than -7/7q-cases (Po0.0001) in the International Prognostic Scoring System (IPSS), 16 where more Int-1-risk cases (Po0.0001) and less highrisk cases (Po0.0001) were diagnosed in der(1;7)(q10;p10) than in -7/7q-cases. In accordance with this was that bone marrow der(1;7)(q10;p10) in myeloid neoplasms M Sanada et al blast counts were significantly lower in der(1;7)(q10;p10) cases than in -7/7q-cases (Po0.0001). Also anemia tended to be less severe at the time of diagnosis in der(1;7)(q10;p10) than in À7/7q-cases (P ¼ 0.0075). More than half cases in both groups were transformed into AML but der(1;7)(q10;p10) cases showed significantly slower progression to AML than À7/7q-cases (P ¼ 0.0043). Accordingly more patients tend to have been treated by chemotherapy in À7/7q-group than in der(1;7)(q10;p10) group (P ¼ 0.049). In total, 57 deaths had occurred during the observation period. Infection was the most common cause of deaths in the der(1;7)(q10;p10) group without leukemic transformation (11 of 16 informative cases), whereas MDS patients were more frequently transformed to AML before death in the À7/7q-group (14/22 in À7/7q-vs 14/35 in der(1;7)(q10;p10)).
Allogeneic stem cell transplantation was performed in two der(1;7)(q10;p10) and three À7/7q-cases. The two der(1;7)(q10;p10) cases survived 1184 and 1508 days after transplantation, whereas two of the three À7/7q-cases succumbed to death within a year due to relapse or complication of the transplantation. Among non-transplanted cases, the der(1;7)(q10;p10) group showed significantly better clinical outcome than other À7/7q-cases, although there was significant heterogeneity with regard to therapies. The median overall survivals were 710 and 272 days in der(1;7)(q10;p10) and other -7/7q-cases, respectively (Po0.0001) (Figure 1) . In univariate analyses of all MDS cases, 410% blast counts (P ¼ 0.0006) and cytopenia in two or more lineages (P ¼ 0.0189) were also extracted as significant risk factors. However, after the backward step-wise liner regressions, only À7/7q-karyotypes (Po0.0001) Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; Eosino, Median eosinophil count; Hb, median hemoglobin level; MDS, myelodysplastic syndrome; MLL, mixed lineage leukemia; MPD, myeloproliferative disorders; NS, not specified; PB, peripheral blood; PLT, median platelet count; WBC, median white blood cell count. *Non-Asian cases from the Mitelman database of chromosome aberrations in cancer. **P-values are calculated between der(1;7)(q10;p10) and À7/7q-cases in the current series or ***P-values between ours and Mittelman's der(1;7)(q10;p10) cases.
der(1;7)(q10;p10) in myeloid neoplasms M Sanada et al and 60 years or more ages (P ¼ 0.0148) were extracted as independently significant risk factors, indicating der(1;7) (q10;p10) and À7/7q-karyotypes define separate risk groups (Table 3) .
Mutation of runx1 and N-ras genes
Since high rates of runx1 mutations have recently been reported in association with À7/7q-cases, 19, 26, 27 we examined mutation status of runx1 in 20 der(1;7)(q10;p10) as well as 20 À7/7q-cases together with additional 20 MDS cases without cytogenetic abnormalities. More runx1 mutations were found in der(1;7)(q10;p10), but it was not significant (7 der(1;7)(q10;p10), 2 À7/7q-and two other cases with normal karyotypes). There were no correlations between mutations and specific FAB subtypes, blast counts or over all survivals, although the sample numbers being too small. N-ras mutaions were found in one der(1;7)(q10;p10) cases (at codon 12), two À7/7q-cases (at codon 12) and two normal karyotypes (at codons 12 and 13), which are comparable to the rates reported previously in MDS. 20, 28, 29 Literary review of 125 der(1;7)(q10;p10) cases reported previously in the literatures
In total, 164 entries were retrieved from the Mitelman database as having der(1;7)(q10;p10), of which 39 Asian cases were excluded from the further analyses to prevent duplicated retrievals and to explore the ethnic difference in the clinical and cytogenetic pictures of this translocation (Table 1) . They had almost similar demographic and cytogenetic features to the current series, but still showed marked difference in several respects. Compared with Asian cases, the male preponderance Death (infection) 39 (18) 22 (8) Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; CMMoL, chronic myelomonocytic leukemia; Hb, median hemoglobin level; HSCT, hematopoietic stem cell transplantation; IPSS, international prognostic scoring system; MDS, myelodysplastic syndrome; NS, not specified; PLT, median platelet count; RA, refractory anemia; RAEB, refractory anemia with excess of blasts; RAEBt, RAEB in transformation; WBC, median white blood cell count. Figure 1 Comparison of survival between der(1;7)(q10;p10) and other -7/7q-cases in MDS. Kaplan-Meier curves of overall survival in MDS cases are compared between der(1;7)(q10;p10) and other -7/7q-. P-values in log rank tests are shown. Found in more than two lineages as defined by neutrophil count o1800/ml, platelets o10,000/ml, Hb o10 g/dl.
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is not prominent and diagnosis of MDS and del(20q) abnormalities seem to be less common in the Western cases.
Discussion
We retrospectively analyzed 77 der(1;7)(q10;p10) cases in order to disclose clinical and cytogenetic features of this translocation, focusing on comparison to other À7/7q-cases, since loss of 7q material is a cardinal consequence of this unbalanced translocation as well as gain of 1q material. In spite of the common 7q loss, we found significant differences between both cytogenetic groups in terms of hematological pictures, clinical outcome and cytogenetic characteristics. der(1;7)(q10;p10) cases tend to be presented with milder anemia, lower blast counts, thus more RA diagnosis, and to show slower progression to AML and have significantly better clinical outcome than other À7/7q-cases. The cytogenetic profiles exhibit a more striking contrast between both groups. der(1;7)(q10;p10) appears as the sole chromosomal abnormality in more than half cases and if not, the additional abnormalities are limited in number and variation, consisting mostly of trisomy 8 and loss of 20q, although the latter has not been described in the Western literatures.
14 In contrast, À7/7q-as the sole abnormality is less common in adult cases but more likely to coexist with other frequently complex abnormalities of partial karyotypes. 4 Common additional abnormalities in À7/7q-cases include À5/5q-, which predicts grave clinical outcomes among À7/7q-group 30 but is rarely found in der(1;7)(q10;p10) cases. Comparison with der(1;7)(q10;p10) cases reported from the Western countries mostly confirmed the results from our series, but also disclosed a marked contrast between both series. Extreme male predisposition and the common 20q abnormality in our series may indicate that genetic or ethnic background play an important role in the pathogenesis of der(1;7)(q10;p10) positive neoplasms. In our series only two of nine female patients with der(1;7)(q10;p10) are de novo cases.
In the past studies, involving relatively small numbers of patients, reported very poor prognosis for this translocation, typically showing less than 1 year of median survival. 3, 14, 15 However, in the current study including 64 der(1;7)(q10;p10) cases, it appears to have better clinical outcome than reported previously, where the survival curve is roughly overlapped with that of the Int-2 IPSS category with a median survival of 23 months for der(1;7)(q10;p10) cases, which was significantly longer than 9 months of À7/7q-positive MDS cases. This may be explained by the fact that À7/7q-cases showed higher bone marrow blast counts and lower hemoglobin concentration than der(1;7)(q10;p10) cases, which were extracted as significant risk factors in univariate analyses (Table 3) . Unexpectedly, however, in multivariate analysis using backward stepwise selection of covariates, only the À7/7q-karyotypes and 60 years or more ages were selected as independent risk factors. Indeed, when the effects of blast counts and cytopenia were adjusted by a proportional hazard model, difference in karyotypes still remains to be significant (P ¼ 0.0034). These observations suggest that der(1;7)(q10;p10) defines a separate prognostic group that shows significantly better clinical outcome than À7/7q-cases and also indicate a possibility that the der(1;7)(q10;p10) may be more appropriately assigned to an intermediate rather than high-risk karyotype in the IPSS 16 or GCEGCH 17 scoring system for better prediction of prognosis. Unfortunately, however, we were not able to test the latter possibility using our series due to a small number of the cases.
With regard to the pathogenetic role of der(1;7)(q10;p10), no specific molecular targets have been identified for this translocation. Since their breakpoints are distributed widely within the large (B0.5-3 Mb) alphoid cluster regions on the centromeres of chromosome 1 and chromosome 7, 10 no specific gene target at the breakpoints is likely to be involved in the recombination event, but loss of 7q and/or gain of 1q should play a role in the pathogenesis of this translocation. In this point of views, it may be worth mentioning that gains of 1q material are also among recurrent chromosomal abnormalities in MDS. 6, 31 Of particular note is that similar 'dicentric' translocations are found in MDS and most frequently involve chromosome 1, resulting in trisomy 1q. 15 On the other hand, it is still open to questions whether additional genetic hits are required to develop der(1;7) (q10;p10)-positive MDS. According to the cytogenetic profiles of der(1;7)(q10;p10) and À7/7q-cases, different pathogenetic models might be postulated in both cytogenetic groups. der(1;7)(q10;p10) represents a relatively early genetic event and a few additional genetic insults, including þ 8 and/or 20q-, could be involved in the neoplastic evolution. On the other hand, À7/7q-is likely to be shared by more heterogeneous subgroups and could be a later genetic event during neoplastic process which shows discrete cytogenetic profiles from those involved in der(1;7)(q10;p10). Runx1 and N-ras genes seem to be among common targets of both cytogenetic groups. Especially, a relatively high incidence of runx1 mutations (7/20) in our der(1;7)(q10;p10) series should be further confirmed, considering a possible link between runx1 mutations and 7q loss. 19, 26 Conclusion der(1;7)(q10;p10) defines a unique clinicopathological entity of myeloid neoplasm having a distinct cytogenetic profile and clinical picture. In our study on heterogeneous MDS patients, their clinical outcome is not as bad as reported previously, but still poor with 23 months of median survival, which argues for importance of stem cell transplantation as a potentially curative treatment, and also for development of novel therapeutic approaches.
